Core Insights - Rackspace Technology announced the appointment of Gajen Kandiah as the new CEO and granted him inducement equity awards [1][2] Equity Awards - Mr. Kandiah received 4,000,000 restricted stock units (RSUs) and non-qualified stock options to purchase 6,000,000 shares of common stock [2] - The stock options have an exercise price of $1.30 per share, equal to the closing price on the grant date, with a maximum term of ten years [2] - The RSUs and stock options will vest in equal annual installments on September 3 for the years 2026, 2027, 2028, and 2029, contingent on Mr. Kandiah's continued employment [2] Compliance and Approval - The equity awards were granted as an inducement material to Mr. Kandiah's employment, in accordance with Nasdaq Listing Rule 5635(c)(4) [3] - The awards were approved by a majority of the independent members of the board of directors, outside of the shareholder-approved equity incentive plan [3] Company Overview - Rackspace Technology is a leading provider of hybrid multicloud technology services and AI solutions, focusing on designing, building, and operating cloud environments across major technology platforms [4] - The company partners with customers at every stage of their cloud journey, enabling modernization of applications, product development, and adoption of innovative technologies [4]

Core Insights - Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies for inherited retinal diseases and small molecule therapies for other ophthalmic disorders [1][3] - The company granted equity awards to two new non-executive employees as an inducement for employment, consisting of stock options and restricted stock units (RSUs) [1][2] Equity Awards Details - The equity awards include stock options for 240,000 shares and 150,000 RSUs, with the stock options having an exercise price of $0.94, equal to the closing price on the grant date [2] - Stock options vest over four years, with 25% vesting on the one-year anniversary and the remaining 75% vesting quarterly thereafter; RSUs vest in four equal installments on each anniversary of the grant date [2] Company Pipeline - Opus Genetics is developing AAV-based gene therapies targeting inherited retinal diseases such as Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa [3] - The lead candidate, OPGx-LCA5, is in a Phase 1/2 trial for LCA5-related mutations and has shown promising early results [3] - Additional programs include OPGx-BEST1 for BEST1-related retinal degeneration and a Phase 3-ready small molecule therapy for diabetic retinopathy, developed under a Special Protocol Assessment with the FDA [3] - The company is also advancing Phentolamine Ophthalmic Solution 0.75%, which is approved for one indication and is being studied in two Phase 3 programs for presbyopia and dim light vision disturbances [3]